[HTML][HTML] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors

J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options. …

[HTML][HTML] Development of targeted alpha particle therapy for solid tumors

…, DN Pandya, MM Budzevich, G El-Haddad… - Molecules, 2019 - mdpi.com
Targeted alpha-particle therapy (TAT) aims to selectively deliver radionuclides emitting α-particles
(cytotoxic payload) to tumors by chelation to monoclonal antibodies, peptides or small …

18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer

…, Y Xiu, QY Jian, A Takalkar, G El-Haddad… - Journal of Nuclear …, 2004 - Soc Nuclear Med
The purpose of this study was to assess the role of PET with 18 F-FDG in differentiating benign
from metastatic adrenal masses detected on CT or MRI scans of patients with lung cancer…

Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders

G El-Haddad, H Zhuang, N Gupta, A Alavi - Seminars in nuclear medicine, 2004 - Elsevier
Fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) has evolved from a
research imaging modality assessing brain function in physiologic and pathologic states to a …

[HTML][HTML] Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer

…, N Vaishampayan, G El-Haddad… - … England Journal of …, 2021 - Mass Medical Soc
Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature

R Kumar, Y Xiu, A Mavi, G El-Haddad… - Clinical Nuclear …, 2005 - journals.lww.com
Primary adrenal lymphoma is an extremely rare entity. Only 70 cases have been reported in
the English literature. Most of the patients are elderly men with bilateral adrenal masses …

NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy

TA Hope, L Bodei, JA Chan, G El-Haddad… - Journal of Nuclear …, 2020 - Soc Nuclear Med
MATERIALS AND METHODS Systematic Review To inform the development of these guidelines,
a systematic review of evidence was performed. We followed the Preferred Reporting …

Radiosensitivity differences between liver metastases based on primary histology suggest implications for clinical outcomes after stereotactic body radiation therapy

KA Ahmed, JJ Caudell, G El-Haddad… - International Journal of …, 2016 - Elsevier
Purpose/Objectives Evidence from the management of oligometastases with stereotactic body
radiation therapy (SBRT) reveals differences in outcomes based on primary histology. We …

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

…, LT Nordquist, N Vaishampayan, G El-Haddad… - 2021 - ascopubs.org
LBA4 Background: Despite recent therapeutic advances, metastatic castration-resistant
prostate cancer (mCRPC) remains invariably fatal. Prostate-specific membrane antigen (PSMA) …

Embolotherapy for neuroendocrine tumor liver metastases: prognostic factors for hepatic progression-free survival and overall survival

JX Chen, S Rose, SB White, G El-Haddad… - Cardiovascular and …, 2017 - Springer
Purpose The purpose of the study was to evaluate prognostic factors for survival outcomes
following embolotherapy for neuroendocrine tumor (NET) liver metastases. Materials and …